MX389020B - Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo. - Google Patents

Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo.

Info

Publication number
MX389020B
MX389020B MX2016006955A MX2016006955A MX389020B MX 389020 B MX389020 B MX 389020B MX 2016006955 A MX2016006955 A MX 2016006955A MX 2016006955 A MX2016006955 A MX 2016006955A MX 389020 B MX389020 B MX 389020B
Authority
MX
Mexico
Prior art keywords
treating
host disease
methods
chronic graft
preventing
Prior art date
Application number
MX2016006955A
Other languages
English (en)
Spanish (es)
Other versions
MX2016006955A (es
Inventor
Bruce R Blazar
Ryan Flynn
Original Assignee
Pharmacyclics Llc
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc, Univ Minnesota filed Critical Pharmacyclics Llc
Publication of MX2016006955A publication Critical patent/MX2016006955A/es
Publication of MX389020B publication Critical patent/MX389020B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
MX2016006955A 2013-12-02 2014-12-02 Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo. MX389020B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US201461973178P 2014-03-31 2014-03-31
PCT/US2014/068177 WO2015084857A1 (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Publications (2)

Publication Number Publication Date
MX2016006955A MX2016006955A (es) 2016-09-07
MX389020B true MX389020B (es) 2025-03-20

Family

ID=53270044

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006955A MX389020B (es) 2013-12-02 2014-12-02 Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo.
MX2022000209A MX2022000209A (es) 2013-12-02 2016-05-27 Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000209A MX2022000209A (es) 2013-12-02 2016-05-27 Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante.

Country Status (14)

Country Link
US (6) US20150157634A1 (OSRAM)
EP (1) EP3076975A4 (OSRAM)
JP (5) JP2017501140A (OSRAM)
KR (2) KR20160085817A (OSRAM)
CN (2) CN105939717B (OSRAM)
AU (4) AU2014360758B2 (OSRAM)
BR (1) BR112016012158A2 (OSRAM)
CA (2) CA2932255C (OSRAM)
EA (1) EA201691020A1 (OSRAM)
IL (4) IL292522A (OSRAM)
MX (2) MX389020B (OSRAM)
PH (2) PH12020552048A1 (OSRAM)
TW (3) TWI743019B (OSRAM)
WO (1) WO2015084857A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150015021A (ko) 2012-06-04 2015-02-09 파마시클릭스, 인코포레이티드 브루톤 타이로신 키나아제 저해제의 결정 형태
KR102357526B1 (ko) 2013-10-25 2022-02-04 파마싸이클릭스 엘엘씨 이식편 대 숙주 질환의 치료 및 예방 방법
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
EP3432879B1 (en) 2016-03-22 2021-01-06 Mayo Foundation for Medical Education and Research Using fatty acid synthase inhibitors to treat fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
WO2018075888A1 (en) * 2016-10-21 2018-04-26 Regents Of The University Of Minnesota Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
WO2022119931A1 (en) * 2020-12-01 2022-06-09 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)
EP4284434A4 (en) * 2021-01-30 2024-12-25 BeiGene Switzerland GmbH METHODS FOR TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
BRPI0621027A2 (pt) * 2006-01-13 2011-11-29 Pharmacyclics Inc composto, composição farmacêutica
ES2673973T3 (es) * 2006-09-22 2018-06-26 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
AU2009270856B2 (en) * 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
US8765754B2 (en) * 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
WO2011026132A2 (en) * 2009-08-31 2011-03-03 1/3Acamplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
KR101580714B1 (ko) * 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
WO2013008095A1 (en) * 2011-07-08 2013-01-17 Novartis Ag Novel pyrrolo pyrimidine derivatives
EP2836214B1 (en) * 2012-04-11 2018-06-27 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
EP3903820B1 (en) * 2012-05-25 2025-05-07 Sloan-Kettering Institute for Cancer Research An anti-ceramide antibodies
CA2898472C (en) * 2013-02-15 2023-03-07 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
KR102357526B1 (ko) * 2013-10-25 2022-02-04 파마싸이클릭스 엘엘씨 이식편 대 숙주 질환의 치료 및 예방 방법
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
JP2017501140A (ja) 2017-01-12
TW202402295A (zh) 2024-01-16
CA2932255C (en) 2023-10-10
AU2022203810A1 (en) 2022-06-23
CA2932255A1 (en) 2015-06-11
JP2020105181A (ja) 2020-07-09
JP2025118595A (ja) 2025-08-13
BR112016012158A2 (pt) 2017-09-26
MX2022000209A (es) 2022-02-03
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
TWI743019B (zh) 2021-10-21
KR20160085817A (ko) 2016-07-18
JP2023029899A (ja) 2023-03-07
US20230100137A1 (en) 2023-03-30
US20150157634A1 (en) 2015-06-11
WO2015084857A1 (en) 2015-06-11
AU2022203810B2 (en) 2024-10-03
KR20230104754A (ko) 2023-07-10
IL292522A (en) 2022-06-01
AU2014360758B2 (en) 2020-03-26
MX2016006955A (es) 2016-09-07
JP2024072291A (ja) 2024-05-27
EP3076975A4 (en) 2017-05-03
PH12020552048A1 (en) 2022-05-11
EP3076975A1 (en) 2016-10-12
IL276683A (en) 2020-09-30
US20180078558A1 (en) 2018-03-22
KR20230104754A9 (ko) 2024-11-15
EA201691020A1 (ru) 2017-01-30
CN105939717A (zh) 2016-09-14
CN105939717B (zh) 2019-09-13
US20250381188A1 (en) 2025-12-18
CA3210338A1 (en) 2015-06-11
IL315228A (en) 2024-10-01
CN110478353B (zh) 2022-12-30
US20240293409A1 (en) 2024-09-05
PH12016501051A1 (en) 2016-08-15
AU2024278490A1 (en) 2025-01-09
AU2014360758A1 (en) 2016-06-16
US20210177854A1 (en) 2021-06-17
CN110478353A (zh) 2019-11-22
AU2020204276A1 (en) 2020-07-16
IL245715A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
MX389020B (es) Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo.
ZA202208792B (en) Methods of treating and preventing graft versus host disease
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
CL2015003731A1 (es) Inhibidores de bromodominios
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
CR20150047A (es) Anticuerpos anti-cd22 e inmunoconjugados
IL235607A0 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
UY4235Q (es) Configuración aplicada en zapato
MX370924B (es) Composiciones para modular la expresión de c9orf72.
EA201790398A1 (ru) Способы лечения заболевания печени
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EA201400178A1 (ru) Лечение рака молочной железы
MX384909B (es) Un anticuerpo anti-tau para usarse al tratar una tauopatía.
MX2021015735A (es) Composiciones de nucleasa terapeuticas y metodos.
BR112013024211A2 (pt) tratamento de tumores sólidos
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112014008203A2 (pt) métodos e sistemas para identificação e tratamento de tumores sensíveis á antiprogestina
BR112014012498A2 (pt) anticorpo anti-cd20 e método para o tratamento do câncer
UY33938A (es) Artículo para fumar que incluye dos o más segmentos de filtro
BR112013024363A2 (pt) método, e aparelho
DK2988760T3 (da) C. novyi til behandlingen af faste tumorer i mennesker
BR112013029484A2 (pt) método para o tratamento de tumores sólidos avançados
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
MX374415B (es) Composiciones y métodos para identificar un riesgo de cáncer en un sujeto.